Keytruda checklist 2025

Show details

4.7 out of 5

62 votes

The document is a Patient Monitoring Checklist for healthcare providers to track signs and symptoms of adverse reactions in patients receiving KEYTRUDA, a treatment for unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC). It outlines indications, safety information, common side effects, and specific immune-mediated adverse reactions that may occur during treatment. The checklist emphasizes the importance of monitoring patients before each infusion and during follow-up visits.

Here's how it works

01. Edit your keytruda checklist online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send keytruda patient checklist via email, link, or fax. You can also download it, export it or print it out.

The best way to modify Keytruda checklist in PDF format online

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Adjusting documents with our extensive and intuitive PDF editor is easy. Adhere to the instructions below to fill out Keytruda checklist online easily and quickly:

Sign in to your account. Log in with your credentials or create a free account to test the service before choosing the subscription.
Import a form. Drag and drop the file from your device or add it from other services, like Google Drive, OneDrive, Dropbox, or an external link.
Edit Keytruda checklist. Quickly add and underline text, insert images, checkmarks, and icons, drop new fillable areas, and rearrange or remove pages from your document.
Get the Keytruda checklist accomplished. Download your modified document, export it to the cloud, print it from the editor, or share it with other people using a Shareable link or as an email attachment.

Take advantage of DocHub, the most straightforward editor to promptly handle your paperwork online!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

What labs to monitor with KEYTRUDA?

Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated.

What not to do while on KEYTRUDA?

Keytruda may also cause liver damage as a side effect. This means that drinking alcohol during Keytruda treatment may increase the risk of liver problems. Alcohol may also increase the risk of cancer recurrence (coming back after treatment) or development of new cancers.

Who is a candidate for KEYTRUDA?

KEYTRUDA may be used alone as your first treatment when your lung cancer has not spread outside your chest (stage III) and you cannot have surgery or chemotherapy with radiation, or your NSCLC has spread to other areas of your body (advanced NSCLC), and your tumor tests positive for PD-L1 and does not have an

What to expect with KEYTRUDA infusion?

Common side effects of KEYTRUDA when given with enfortumab vedotin include rash; tingling or numbness of the arms or legs; feeling tired; itching; diarrhea; hair loss; weight loss; decreased appetite; dry eye; nausea; constipation; changes in sense of taste; and urinary tract infection.

What are the guidelines for KEYTRUDA?

The recommended dose of KEYTRUDA in adults is 200 mg administered after dilution as an IV infusion over 30 minutes every 3 weeks or 400 mg administered after dilution as an IV infusion over 30 minutes every 6 weeks until disease progression, unacceptable toxicity, or up to 24 months.

keytruda patient monitoring checklist

KEYTRUDA patient information pdf Signs that Keytruda is working OPDIVO Checklist Keytruda cost How is Keytruda administered Keytruda treatment Keytruda side effects Keytruda rash pictures

Related forms

be ready to get more

Complete this form in 5 minutes or less

Get form

What is qualifying for KEYTRUDA?

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death ligand 1 (PD⁠-⁠L1) [combined positive score (CPS) 1] as determined by an FDA-approved test.

Is KEYTRUDA given every 3 or 6 weeks?

In adults with certain cancers, KEYTRUDA is usually given every 3 weeks or every 6 weeks depending on the dose that you are receiving. In children, KEYTRUDA is usually given every 3 weeks. Talk to your doctor about the treatment schedule that is right for you. Your doctor can help answer questions.

Keytruda checklist 2025

Here's how it works

The best way to modify Keytruda checklist in PDF format online

Complete this form in 5 minutes or less

Got questions?

What labs to monitor with KEYTRUDA?

What not to do while on KEYTRUDA?

Who is a candidate for KEYTRUDA?

What to expect with KEYTRUDA infusion?

What are the guidelines for KEYTRUDA?

Complete this form in 5 minutes or less

People also ask

What is qualifying for KEYTRUDA?

Is KEYTRUDA given every 3 or 6 weeks?

keytruda medication checklist

Try more PDF tools